Royalty Pharma (NASDAQ:RPRX) Price Target Raised to $58.00 at JPMorgan Chase & Co.

Royalty Pharma (NASDAQ:RPRX) had its price objective increased by JPMorgan Chase & Co. from $50.00 to $58.00 in a research report report published on Thursday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

Several other equities analysts have also commented on the company. TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, May 1st. UBS Group increased their price objective on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Finally, Citigroup increased their price objective on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $53.71.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $50.20 on Thursday. The firm has a market capitalization of $28.96 billion, a P/E ratio of 34.15, a P/E/G ratio of 3.24 and a beta of 0.40. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88. The stock’s 50-day simple moving average is $47.62 and its two-hundred day simple moving average is $42.75. Royalty Pharma has a twelve month low of $32.15 and a twelve month high of $51.65.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $631.00 million for the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a return on equity of 29.49% and a net margin of 33.88%. As a group, equities analysts anticipate that Royalty Pharma will post 5.08 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $0.235 per share. The ex-dividend date is Friday, May 15th. This represents a $0.94 annualized dividend and a yield of 1.9%. Royalty Pharma’s dividend payout ratio is currently 69.63%.

Insiders Place Their Bets

In related news, CFO Terrance P. Coyne sold 34,791 shares of the stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total transaction of $1,731,895.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 139,164 shares of company stock worth $6,624,902. Corporate insiders own 18.84% of the company’s stock.

Institutional Investors Weigh In On Royalty Pharma

Institutional investors and hedge funds have recently bought and sold shares of the business. LM Advisors LLC purchased a new stake in Royalty Pharma in the 4th quarter worth approximately $26,000. Lloyd Advisory Services LLC. purchased a new stake in Royalty Pharma in the 4th quarter worth approximately $30,000. Smartleaf Asset Management LLC lifted its holdings in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 790 shares during the period. Private Trust Co. NA lifted its holdings in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 288 shares during the period. Finally, Blue Trust Inc. lifted its holdings in Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 437 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Key Stories Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Citigroup raised its price target on RPRX to $66 and initiated/maintained a “buy” rating, implying material upside vs. the current share price — a clear near-term bullish signal from a major bank. Benzinga
• Positive Sentiment: JPMorgan raised its price target to $58 and moved to “overweight,” adding institutional support to the stock’s outlook. Benzinga
• Positive Sentiment: Q1 results: EPS beat consensus ($1.30 vs. ~$1.22) and management struck an upbeat tone on the earnings call; Royalty raised full‑year 2026 Portfolio Receipts guidance to $3,325M–$3,450M and reported strong cash flow (net cash from ops $718M). These items support longer‑term earnings visibility. Press Release
• Neutral Sentiment: Royalty announced participation in multiple investor conferences in May — gives management additional forums to reinforce guidance and pipeline/portfolio messaging. GlobeNewswire
• Neutral Sentiment: Full transcripts and recaps of the Q1 call are available (Seeking Alpha, Yahoo/TipRanks, Zacks) — useful for digging into revenue mix, deal cadence and management commentary that will guide near-term estimates. Earnings Transcript (Yahoo)
• Negative Sentiment: Revenue missed some analyst expectations: reported revenue (~$631M) came in below certain street estimates (~$882M), which may fuel profit‑taking and explain downward pressure despite the EPS beat and upgrades. Press Release (financials)

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.